anti-MAGE-A4/anti-CD3 bispecific antibody RO7617991

A bispecific T-cell engaging antibody directed against both the tumor-associated antigen (TAA) melanoma-associated antigen A4 (MAGE-A4) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-MAGE-A4/anti-CD3 bispecific antibody RO7617991 simultaneously binds to both CD3 on cytotoxic T lymphocytes (CTLs) and MAGE-A4 on MAGE-A4-expressing tumor cells. This activates and redirects CTLs to MAGE-A4-expressing tumor cells, which results in the CTL-mediated cell death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.